News: IMM Immutep Reports Phase IIb Final AIPAC Study Results, page-72

We have met the expectations we had from results of Dec 2020 when AIPAC was resurrected. Just that people had no expectation from March 2020 going into ASCO, but this time some thought results should further improve by light years. NO,!!! As I have said all along since Dec 2020, all we had to do was get the same results as a more complete data. And this is what we have ACHIEVED. ANYONE who knows about clinical trials and biotech would tell you the same. Its just that some mob, who have no clue, expect miracle. SOOOO F'n glad they only hold a small portion of the shares that they can do what they like with day in day out. The rest, majority of the shares, ARE HOLDING FIRM GROUNDS. Just look at the long term trend and see how the baseline nicely trending the upward trend, ... the baseline that is held by backbone investors, nicely reflects the value. I cannot be happier with today's results as it MET my expectations, and in fact even more.